This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.93% per year. These returns cover a period from January 1, 1988 through October 6, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
biotechnology: Archive
2025's Top 3 Breakout Stocks for Active Traders: Don't Miss Out!
by Tirthankar Chakraborty
ORLA, FIGS and CMPX emerge as breakout candidates as traders scan for stocks nearing or clearing key resistance levels.
ORLANegative Net Change FIGSNegative Net Change CMPXNegative Net Change
biotechnology medical retail
Will Librexia ACS Study Setback Dent BMY's Cardiovascular Portfolio?
by Ekta Bagri
BMY ends its Librexia ACS study after an interim review shows milvexian is unlikely to meet goals, while other late-stage studies continue.
BMYPositive Net Change JNJPositive Net Change PFENegative Net Change CYTKNegative Net Change
biotechnology biotechs medical pharmaceuticals
COGT Stock Skyrockets 120% in a Month: Here's What You Need to Know
by Zacks Equity Research
Cogent Biosciences soars as its bezuclastinib combo delivers strong phase III GIST results, driving momentum toward key regulatory filings.
ADMAPositive Net Change EDITNegative Net Change COGTNegative Net Change ARQTNegative Net Change
biotechnology biotechs medical oncology-screening pharmaceuticals
MRK HIV Regimen Meets Goal in New Study, Gains EU Nod for Keytruda SC
by Zacks Equity Research
Merck reports strong new HIV study results showing non-inferiority of DOR/ISL to Gilead's Biktarvy and secures an EU approval for its faster-to-administer SC version of Keytruda.
MRKNegative Net Change GILDNegative Net Change ADMAPositive Net Change ARQTNegative Net Change
biotechnology biotechs medical oncology-screening pharmaceuticals
REGN Gets EC Nod for Libtayo Label Expansion, FDA Clears Monthly Eylea HD
by Zacks Equity Research
Regeneron gains EC approval to expand Libtayo's use in high-risk CSCC. The FDA approves Eylea HD the treatment of patients with macular edema following retinal vein occlusion.
REGNPositive Net Change SNYNegative Net Change RHHBYNegative Net Change BAYRYNegative Net Change
biotechnology biotechs medical pharmaceuticals
5 Stocks With Recent Price Strength Amid Wall Street Volatility
by Nalak Das
CSTL, IDN, PANL, FSRL and PRM are showing sharp price strength amid renewed Wall Street volatility.
IDNNegative Net Change PANLNegative Net Change FSRLPositive Net Change CSTLPositive Net Change PRMNegative Net Change
biotechnology finance industrial-products transportation
BIAF Stock Dips After Q3 Earnings Reflect Lower Sales and Wider Loss
by Zacks Equity Research
bioAffinity's third-quarter 2025 performance shows lower sales and a wider loss as it pivots to focus on CyPath Lung and expands VA system adoption.
BIAFNegative Net Change
biotechnology biotechs earnings medical
VNDA Stock Jumps on Upbeat Tradipitant Data Cutting GLP-1 Side Effects
by Zacks Equity Research
Vanda Pharmaceuticals stock rallies after phase II data show tradipitant sharply cuts Wegovy-related nausea and vomiting in overweight and obese adults.
NVONegative Net Change VNDANegative Net Change ADMAPositive Net Change ARQTNegative Net Change
biotechnology biotechs medical pharmaceuticals
BAYRY Obtains Approval for Hormone Free VMS Treatment Lynkuet in the EU
by Zacks Equity Research
Bayer wins EU approval for Lynkuet, expanding its pharma portfolio with a hormone-free treatment for moderate to severe vasomotor symptoms
JNJPositive Net Change ALKSNegative Net Change BAYRYNegative Net Change FOLDNegative Net Change
biotechnology medical pharmaceuticals
VTYX Stock Skyrockets 156% in a Month: Here's What You Need to Know
by Zacks Equity Research
Ventyx Biosciences stock jumps 156% as its mid-stage obesity and CV risk study achieves key safety, tolerability, anti-inflammatory and CV risk reduction goals.
NVONegative Net Change ADMAPositive Net Change ARQTNegative Net Change VTYXPositive Net Change
biotechnology biotechs medical pharmaceuticals
Alector Stock Plummets 63% in a Month: Here's What You Need to Know
by Zacks Equity Research
ALEC stock plunges after its dementia candidate fails to slow disease progression in a late-stage study, prompting job cuts and a strategic pipeline shift.
GSKNegative Net Change ADMAPositive Net Change ALECNegative Net Change ARQTNegative Net Change
biotechnology biotechs medical pharmaceuticals
Top 3 Genomics Stocks to Consider for Your Portfolio
by Ekta Bagri
Genomics gains momentum as EDIT, SANA, and PACB emerge as standout picks amid rapid advances in sequencing and gene editing.
ILMNNegative Net Change PACBPositive Net Change EDITNegative Net Change NTLANegative Net Change CRSPNegative Net Change SANANegative Net Change
biotechnology gene-editing genetics genomics medical pharmaceuticals
2 ETFs to Watch for Outsized Volume on Biotechnology Stocks
by Aparajita Dutta
Biotech ETFs PBE and FBT saw trading volumes soar to over four times their averages, signaling rising interest amid a down day for major indexes.
FBTPositive Net Change PBEPositive Net Change
biotechnology etfs
NVO Down 10% in 3 Months: Is This an Indication to Sell the Stock?
by Ahan Chakraborty
Novo Nordisk stock falls 10% in three months as guidance cuts, GLP-1 rivalry and looming U.S. price resets cloud growth and elevate execution risks.
NVONegative Net Change LLYNegative Net Change AMGNNegative Net Change VKTXNegative Net Change
biotechnology biotechs medical pharmaceuticals
MiMedx (MDXG) Just Flashed Golden Cross Signal: Do You Buy?
by Zacks Equity Research
Is it a good or bad thing when a stock experiences a golden cross technical event?
MDXGPositive Net Change
ad-tech artificial-intelligence automation autonomous-vehicles batteries biotechnology cell-therapy creator-economy crispr daily-movers dna-sequencing electric-vehicles fin-tech furniture-retailers gambling gene-editing gene-therapy genetic-testing genomics home-builder home-buying-apps immuno-therapy iot medical-devices messenger-rna mobile moving-average-crossover oncology-screening payments ride-hailing robotics saas self-driving-cars smart-health social-media stock-price-movement stocks-moving-today vaccines
BMY Stock Down on Discontinuation of ACS Clinical Study With JNJ
by Zacks Equity Research
BMY shares drop after halting the Librexia ACS trial, though other milvexian studies continue with top-line data expected in 2026.
BMYPositive Net Change JNJPositive Net Change CYTKNegative Net Change BNTXNegative Net Change
biotechnology biotechs medical pharmaceuticals
Zacks.com featured highlights include Perimeter Solutions, Interface, Castle Biosciences and Great Lakes Dredge & Dock
by Zacks Equity Research
Perimeter Solutions and peers stand out as rising cash-flow plays, with analysts boosting earnings estimates across these under-the-radar names.
GLDDNegative Net Change TILENegative Net Change CSTLPositive Net Change PRMNegative Net Change
biotechnology
Nexa Resources S.A. (NEXA)'s Technical Outlook is Bright After Key Golden Cross
by Zacks Equity Research
Should investors be excited or worried when a stock's 50-day simple moving average crosses above the 200-day simple moving average?
NEXANegative Net Change
ad-tech artificial-intelligence automation autonomous-vehicles batteries biotechnology cell-therapy creator-economy crispr daily-movers dna-sequencing electric-vehicles fin-tech furniture-retailers gambling gene-editing gene-therapy genetic-testing genomics home-builder home-buying-apps immuno-therapy iot medical-devices messenger-rna mobile moving-average-crossover oncology-screening payments ride-hailing robotics saas self-driving-cars smart-health social-media stock-price-movement stocks-moving-today vaccines
Twilio (TWLO) Now Trades Above Golden Cross: Time to Buy?
by Zacks Equity Research
Is it a good or bad thing when a stock experiences a golden cross technical event?
TWLONegative Net Change
ad-tech artificial-intelligence automation autonomous-vehicles batteries biotechnology cell-therapy creator-economy crispr daily-movers dna-sequencing electric-vehicles fin-tech furniture-retailers gambling gene-editing gene-therapy genetic-testing genomics home-builder home-buying-apps immuno-therapy iot medical-devices messenger-rna mobile moving-average-crossover oncology-screening payments ride-hailing robotics saas self-driving-cars smart-health social-media stock-price-movement stocks-moving-today vaccines
GILD's Investigational Regimen for HIV Treatment Meets Primary Goal
by Zacks Equity Research
Gilead's ARTISTRY-1 success boosts shares as its once-daily bictegravir/lenacapavir combo proves non-inferior to complex regimens.
GSKNegative Net Change ALKSNegative Net Change GILDNegative Net Change FOLDNegative Net Change
biotechnology biotechs medical pharmaceuticals
Kodiak Q3 Loss Wider Than Expected, Pipeline Development in Focus
by Zacks Equity Research
KOD posts a wider Q3 loss as rising R&D spend fuels advances across its eye-disease pipeline ahead of key data readouts.
ANIPNegative Net Change ADMAPositive Net Change KODPositive Net Change ARQTNegative Net Change
biotechnology biotechs earnings medical
Cytokinetics Gains 11.4% in a Week: Is There More Room for Growth?
by Zacks Equity Research
Cytokinetics' shares surge to a 52-week high as investor optimism grows over FDA approval prospects for aficamten.
BMYPositive Net Change ALKSNegative Net Change FOLDNegative Net Change CYTKNegative Net Change
biotechnology biotechs medical pharmaceuticals
BMY's Growth Portfolio Shines in Q3: Turning Point Ahead?
by Ekta Bagri
Bristol Myers' strong Q3 growth portfolio, led by Opdivo and Reblozyl, helped counter declines in legacy drug sales.
BMYPositive Net Change PFENegative Net Change MRKNegative Net Change
biotechnology biotechs medical pharmaceuticals
Company News for Nov 13, 2025
by Zacks Equity Research
Companies in The News Are: LEGN, ONON, PLTR, ALC
ALCNegative Net Change LEGNNegative Net Change PLTRNegative Net Change ONONNegative Net Change
biotechnology semiconductor
Novartis' Phase III Malaria Study Meets Key Non-Inferiority Endpoint
by Zacks Equity Research
NVS' GanLum meets its phase III goal, showing strong efficacy against drug-resistant malaria and proving non-inferiority to the current standard of care.
NVSNegative Net Change ANIPNegative Net Change ADMAPositive Net Change ARQTNegative Net Change
biotechnology biotechs medical pharmaceuticals